抗体
选项
-
Nipocalimab (anti-FcRn)关联靶标: FCGRT
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 2211985-36-1 -
Rozanolixizumab (anti-FCGRT)关联靶标: FCGRT
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG4SP
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 1584645-37-3 -
Ziltivekimab (anti-IL-6)
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 2226654-05-1 -
Conatumumab (anti-TNFRSF10B)
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 896731-82-1 -
Batoclimab (anti-FcRn)
- 简短描述: Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0EU/mg; Human IgG1(K214R/L234A/L235A); CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG1(K214R/L234A/L235A)
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 2187430-05-1 -
Mapatumumab (anti-TNFRSF10A)关联靶标: TNFRSF10A
- 简短描述: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 亚型: Human IgG2SA
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号 : 658052-09-6 -
-
DR5/CD262 Armenian Hamster mAb
- 简短描述: mAb (MD5-1); Armenian Hamster anti Mouse DR5/CD262 Antibody; Flow, in vitro induction TRAIL-mediated apoptosis, in vivo induction TRAIL-mediated apoptosis; Unconjugated
- 种属反应性: 小鼠(Mouse)
- 亚型: Armenian Hamster IgG
- 宿主种属: 亚美尼亚仓鼠(Armenian hamster)
- 克隆号: MD5-1
- 偶联: Unconjugated
首页
400-620-6333







